Jain Rita 4/A

What Happened

• Rita Jain, a director of First Tracks Biotherapeutics, was granted equity awards on May 12, 2026: 7,000 stock options and 2,500 restricted stock units (RSUs). Both awards are recorded as derivative grants at $0.00 per share (no cash paid at grant).
• This Form 4 is an amendment filed June 12, 2026 to correct the originally reported award amounts; the initial Form 4 was filed May 14, 2026.

Key Details

• Transaction date: May 12, 2026. Report filed/ amended: originally May 14, 2026; amended June 12, 2026 to correct amounts.
• Price: $0.00 per option/RSU (derivative awards); total immediate cash value reported = $0.
• Shares owned after transaction: Not stated in the amended filing.
• Vesting and settlement notes:
  • RSUs (2,500): each RSU converts to one share on settlement for no consideration (F1). All RSUs vest 100% on the Issuer’s 2027 annual meeting date, subject to continued service (F2).
  • Stock options (7,000): vest 1/12 of total shares monthly beginning June 12, 2026 until fully vested, subject to continued service (F3).
• Filing status: This is an amended Form 4 correcting award amounts; the original Form 4 was filed promptly on May 14, 2026.

Context

• These grants are awards (not open‑market purchases or sales). RSUs are contingent rights to receive shares at settlement; options will vest over time and require exercise to convert into shares. Such grants are common for compensation and do not by themselves indicate insider buying or selling.